首页 > 化工企业 > MedChemexpress > 双马来酸盐阿法替尼
MedChemexpress

货号: HY-10261A

双马来酸盐阿法替尼

  • 850140-73-7
  • C32H33ClFN5O11
  • 98%
  • 7日

销 售 价 ¥650.00 /mg

选择规格
  • 10mg
全部
最小起订
1mg
支付方式
e商贷 摩易付

摩贝商家

商家名称
MedChemexpress
所在地区
美国 新泽西 纽瓦克
公司电话
609-2286898
联系手机
18019480960
认证属性
试剂

店内搜索

热销产品

perampanel

(380917-97-5)

¥1540

盐酸纳曲酮

(16676-29-2)

¥400

唑吡坦

(82626-48-0)

¥1023

地西泮

(439-14-5)

¥930

普瑞巴林

(148553-50-8)

¥550

  • 商品详情
  • 商品评价
  • MSDS
信息更新时间:2018.06.10
  • 双马来酸盐阿法替尼
  • 98%
  • 10mg
  • 1 mg
  • 7日
  • HY-10261A
化合物信息 [查看化合物百科]
化合物英文学名 afatinib dimaleate 化合物中文学名 双马来酸盐阿法替尼
CAS号 850140-73-7 分子式 C32H33ClFN5O11
分子量 718.083 精确质量 717.185
LogP 4.536 PSA 241.3
详细描述
产品描述:Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. IC50 value: 0.5 nM/0.4 nM/10 nM/14 nM (EGFR(wt)/EGFR(L858R)/EGFR(L858R/T790M) /HER2) [1] Target: EGFR;EGFR mutant forms; HER2 in vitro: BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2 [1]. All pancreatic cancer cell lines were found to be IGF-IR positive and NVP-AEW541 treatment inhibited the growth of the pancreatic cancer cell lines with IC50 values ranging from 342 nM (FA6) to 2.73 μM (PT45). Interestingly, of the various combinations examined, treatment with a combination of NVP-AEW541 and afatinib was superior in inducing synergistic growth inhibition of the majority of pancreatic cancer cells [2]. in vivo: Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies [1].
产品链接:http://www.medchemexpress.com/AG1024.html
产品链接:http://www.medchemexpress.cn/afatinib-dimaleate.html

该公司尚未提供产品的MSDS报告,下部信息为摩贝百科数据库为您提供的MSDS信息,供您参考。

提醒该企业完善MSDS信息
MSDS

采购信息

双马来酸盐阿法替尼

850140-73-7

*
*
*
*
*
 
 
 

购物车 0

不要让您的购物车空着哦,买试剂买原料
如果您已添加过宝贝,那就赶紧登录查看吧

投诉建议

  • 咨询类别
  • 问题描述
  • 联系人电话
  • 联系人

化工圈APP

二维码

微信公众号

二维码